Amgen (AMGN) Q2 Profit Jumps 21%
(NASDAQ:AMGN), a leading biotechnology company with a wide portfolio of innovative medicines, released its second-quarter 2025 results on August 5, 2025. The headline news was a double-digit jump in profit and a 9% increase in revenue, beating analyst predictions (non-GAAP EPS and GAAP revenue) as strong product launches and pipeline progress boosted sales. Non-GAAP earnings per share came in at $6.02, handily above the $5.28 consensus (non-GAAP), while GAAP revenue hit $9.18 billion compared to the expected $8.94 billion. The quarter stood out for strong top-line growth and further advances in its late-stage drug pipeline, as total revenues increased 9% year-over-year, though lower free cash flow signals an area to watch going forward.
Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q1 2025 earnings report.
Amgen is one of the world’s biggest biotech companies, developing and marketing a range of biologic and biosimilar drugs for conditions such as cancer, cardiovascular disease, rare diseases, and inflammation. Its portfolio includes both well-established products and a wave of newer, innovative drugs that address unmet medical needs.
Source Fool.com
Amgen Inc. Aktie
Amgen Inc. ist ein klarer Community-Favorit mit mehr Buy- als Sell-Einschätzungen.
Für Amgen Inc. sieht die Community ein Kursziel von 308 €, was eine erhebliche Steigerung um über 20% gegenüber dem aktuellen Kurs von 244.35 € bedeutet.
